Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
ORLEX vs CARISOPRODOL
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Orlistat is a reversible inhibitor of gastric and pancreatic lipases, preventing the hydrolysis of dietary triglycerides into absorbable free fatty acids and monoglycerides. This reduces dietary fat absorption by approximately 30%.
Carisoprodol is a centrally acting skeletal muscle relaxant that exerts its effects via modulation of GABA-A receptors, possibly through its active metabolite meprobamate, which is a controlled substance with barbiturate-like activity. It also inhibits interneuronal activity in the descending reticular formation and spinal cord, leading to muscle relaxation.
Weight management (FDA approved for obesity, BMI ≥30 kg/m² or BMI ≥27 kg/m² with risk factors),Off-label: prevention of weight gain in type 2 diabetes
Adjunct to rest, physical therapy, and other measures for the relief of discomfort associated with acute, painful musculoskeletal conditions
Orally, 1-2 tablets (5-10 mg of hydrocodone equivalent) every 4-6 hours as needed for pain; maximum 12 tablets per day.
250-350 mg orally 3 times daily and at bedtime
Terminal elimination half-life: 4-6 hours; in renal impairment, half-life can extend to >12 hours requiring dose adjustment.
Terminal elimination half-life is approximately 2.0 hours for carisoprodol; the active metabolite meprobamate has a half-life of 6-12 hours. Clinical context: Short half-life supports three-times-daily dosing; accumulation of meprobamate with repeated dosing or renal impairment may prolong effects.
Primarily metabolized in the gastrointestinal wall and liver via hydrolysis; minimal systemic absorption. Main metabolites are M1 (4-member lactone ring hydrolysis) and M3 (M1 with a cleaved N-formyl leucine moiety).
Primarily hepatic via CYP2C19; partially metabolized to meprobamate (a Schedule IV controlled substance) by N-dealkylation; also undergoes hydrolysis and subsequent conjugation.
Renal: 70% (as unchanged drug and metabolites); Biliary/Fecal: 30%
Renal: >99% as metabolites (hydroxycarisoprodol and meprobamate) and minor unchanged drug. Fecal: <1%. Biliary: negligible.
99% primarily to albumin and alpha-1-acid glycoprotein
Carisoprodol: approximately 60% bound to plasma proteins (predominantly albumin). Meprobamate: ~20% bound.
0.15-0.2 L/kg, indicating confinement to vascular space; correlates with high protein binding.
Apparent Vd: approximately 0.8 L/kg for carisoprodol (total body water distribution). Clinical meaning: Extensive distribution into tissues; consistent with moderate lipophilicity.
Oral: 90-100% (extensive absorption); no significant first-pass metabolism.
Oral: Approximately 95% absorbed from the GI tract; extensive first-pass metabolism converts ~50% to meprobamate; net bioavailability of parent drug is ~50-60%.
For GFR 30-59 m L/min: administer every 6-8 hours; GFR <30 m L/min: administer every 8-12 hours; avoid use in GFR <15 m L/min.
No specific guidelines; use with caution in severe renal impairment (Cr Cl <30 m L/min) due to increased risk of accumulation.
Child-Pugh Class A: no adjustment; Child-Pugh Class B: reduce dose by 25%; Child-Pugh Class C: avoid use.
Child-Pugh A: no dose adjustment; Child-Pugh B: reduce dose by 50%; Child-Pugh C: avoid use.
Children ≥2 years: 0.1-0.2 mg/kg hydrocodone equivalent orally every 4-6 hours as needed; maximum 10 mg per dose.
Not recommended for use in children under 16 years due to lack of safety and efficacy data.
Initiate at 50% of adult dose, titrate cautiously; monitor for respiratory depression and constipation.
Initiate at 250 mg 3-4 times daily; monitor for sedation and falls; consider reducing dose in frail elderly.
None
None
Hepatotoxicity (rare, but cases of severe liver injury reported),Cholelithiasis (increased risk due to rapid weight loss),Oxalate nephrolithiasis (increased urinary oxalate excretion),Fat-soluble vitamin deficiency (A, D, E, K; supplementation recommended),Gastrointestinal adverse effects (oily spotting, flatus with discharge, fecal urgency, steatorrhea),Interaction with cyclosporine, amiodarone, and antiepileptic drugs
Risk of sedation and dizziness, impairing ability to drive or operate machinery,Potential for abuse and dependence, especially with long-term use; meprobamate is a controlled substance,Withdrawal symptoms including anxiety, insomnia, and seizures upon abrupt discontinuation,Hepatic impairment may alter metabolism; use with caution,May cause serotonin syndrome when used with other serotonergic drugs,Respiratory depression with concurrent use of CNS depressants
Chronic malabsorption syndrome,Cholestasis,Pregnancy (weight loss is not recommended),Hypersensitivity to orlistat or any component
Hypersensitivity to carisoprodol or meprobamate,Acute intermittent porphyria,Concomitant use with MAOIs (potential for hypertensive crisis)
Avoid alcohol completely; ethanol increases acetaminophen hepatotoxicity and potentiates CNS depression from hydrocodone. No specific food restrictions, but high-fat meals may delay absorption; take on an empty stomach for more consistent effects. Maintain adequate hydration to prevent constipation.
Avoid alcohol. No specific food interactions known, but CNS depressant effects may be exacerbated by alcohol or other sedating substances.
ORLEX (codeine/acetaminophen) is contraindicated in all trimesters due to risk of neonatal opioid withdrawal syndrome and acetaminophen hepatotoxicity. First trimester: limited data but no major malformations reported. Second and third trimesters: chronic use may lead to fetal dependence and neonatal abstinence syndrome. During labor, codeine may cause respiratory depression in neonate.
Carisoprodol is classified as FDA Pregnancy Category C. Data from animal studies have shown fetal harm, but no adequate well-controlled studies in pregnant women. First trimester: Limited data suggest a possible increased risk of congenital anomalies, particularly with first-trimester exposure. Second and third trimesters: Use may be associated with neonatal withdrawal syndrome including irritability, tremors, and poor feeding. Avoid use during pregnancy, especially during the first trimester.
Codeine is excreted into breast milk with M/P ratio approximately 2.5. Risk of infant opioid toxicity, especially in ultra-rapid metabolizers; contraindicated in breastfeeding due to potential for infant respiratory depression and sedation. Acetaminophen is safe at low doses.
Carisoprodol and its active metabolite meprobamate are excreted into human breast milk. The milk-to-plasma ratio (M/P) is not well established but considered low. However, potential adverse effects in nursing infants include sedation and withdrawal symptoms. The manufacturer recommends caution; avoid breastfeeding while using carisoprodol due to risk of neonatal sedation.
Elimination half-life of codeine is decreased; effects may be reduced. Acetaminophen metabolism is increased. No standard dosing adjustment recommended due to lack of safety data; avoid use in pregnancy. If unavoidable, use lowest effective dose for shortest duration.
Pharmacokinetic changes during pregnancy (increased volume of distribution, altered hepatic metabolism) may reduce carisoprodol concentrations. However, no specific dose adjustments are recommended due to lack of data and potential fetal risks. Use is not recommended in pregnancy; therefore, dose adjustments are not applicable.
ORLEX is a combination of hydrocodone and acetaminophen; monitor for signs of acetaminophen hepatotoxicity, especially in patients with hepatic impairment or chronic alcohol use. Hydrocodone is a prodrug metabolized by CYP2D6; poor metabolizers may have reduced efficacy, while ultrarapid metabolizers risk toxicity. Use with caution in elderly or debilitated patients due to increased fall risk. Avoid concurrent use with other CNS depressants. Prescribe the lowest effective dose for the shortest duration.
Carisoprodol is centrally acting muscle relaxant that is metabolized to meprobamate, a controlled substance with abuse potential. Avoid in patients with history of substance abuse. Use short-term (2-3 weeks) due to lack of evidence for long-term efficacy. Monitor for sedation and dizziness; avoid concomitant use with other CNS depressants. Taper to discontinue after prolonged use to prevent withdrawal symptoms.
Take exactly as prescribed; do not increase dose or frequency without consulting your doctor.,Do not crush, chew, or break extended-release tablets.,Avoid alcohol while taking ORLEX; it increases risk of liver damage and sedation.,Do not drive or operate heavy machinery until you know how ORLEX affects you.,Discontinue use and seek emergency help if you experience signs of allergic reaction (rash, difficulty breathing) or serotonin syndrome (agitation, hallucinations, rapid heart rate, fever).,Store securely out of reach of children; dispose of unused medication properly.,Contact your doctor if pain persists or worsens after a few days.
Take only as prescribed for short-term relief (usually 2-3 weeks).,Do not increase dose or stop abruptly without consulting doctor.,May cause drowsiness, dizziness, or blurred vision; avoid driving or operating machinery until you know how you react.,Avoid alcohol and other sedatives while taking this medication.,Report any signs of abuse or dependence (e.g., craving, needing higher doses).,Do not share this medication with others due to abuse potential.,Seek medical attention if you experience allergic reactions (rash, itching, swelling) or seizures.
No interactions on record
"The co-administration of pentobarbital, a barbiturate and potent CYP3A4 inducer, with carisoprodol, a prodrug that is metabolized to its active form, meprobamate, via CYP2C19, may lead to reduced plasma concentrations of meprobamate due to pentobarbital-induced upregulation of CYP2C19, potentially diminishing the sedative and muscle relaxant effects of carisoprodol. However, pentobarbital also acts as a central nervous system (CNS) depressant, and additive CNS depression can occur, increasing the risk of excessive sedation, respiratory depression, and impairment of psychomotor function. Clinical outcomes may include altered therapeutic efficacy of carisoprodol and heightened risk of CNS and respiratory adverse effects."
"Carisoprodol, a centrally acting skeletal muscle relaxant, is metabolized primarily by CYP2C19 to its active metabolite meprobamate. Isoniazid, a first-line antitubercular agent, is a known inhibitor of CYP2C19. When coadministered, isoniazid can decrease the metabolism of carisoprodol, leading to increased plasma concentrations of both carisoprodol and meprobamate. This elevation raises the risk of dose-related adverse effects such as sedation, dizziness, and respiratory depression, and may prolong the duration of muscle relaxant action."
"The combination of sulpiride, an atypical antipsychotic with dopamine D2 receptor antagonism and mild serotonin 5-HT4 agonist properties, and carisoprodol, a centrally acting muscle relaxant metabolized to meprobamate (a barbiturate-like sedative-hypnotic), can result in additive central nervous system (CNS) depression, including sedation, dizziness, and psychomotor impairment. Additionally, both drugs may lower the seizure threshold, increasing the risk of seizures. Sulpiride can also prolong the QT interval, and carisoprodol's sedative effects may mask or exacerbate this cardiotoxicity, potentially leading to ventricular arrhythmias such as torsade de pointes."
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about ORLEX vs CARISOPRODOL, answered by our medical review team.
ORLEX is a Muscle relaxant that works by Orlistat is a reversible inhibitor of gastric and pancreatic lipases, preventing the hydrolysis of dietary triglycerides into absorbable free fatty acids and monoglycerides. This reduces dietary fat absorption by approximately 30%.. CARISOPRODOL is a Skeletal Muscle Relaxant that works by Carisoprodol is a centrally acting skeletal muscle relaxant that exerts its effects via modulation of GABA-A receptors, possibly through its active metabolite meprobamate, which is a controlled substance with barbiturate-like activity. It also inhibits interneuronal activity in the descending reticular formation and spinal cord, leading to muscle relaxation.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between ORLEX and CARISOPRODOL depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of ORLEX is: Orally, 1-2 tablets (5-10 mg of hydrocodone equivalent) every 4-6 hours as needed for pain; maximum 12 tablets per day.. The standard adult dose of CARISOPRODOL is: 250-350 mg orally 3 times daily and at bedtime. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between ORLEX and CARISOPRODOL in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. ORLEX is classified as Category C. ORLEX (codeine/acetaminophen) is contraindicated in all trimesters due to risk of neonatal opioid withdrawal syndrome and acetaminophen hepatotoxicity. First trimester: limited dat. CARISOPRODOL is classified as Category A/B. Carisoprodol is classified as FDA Pregnancy Category C. Data from animal studies have shown fetal harm, but no adequate well-controlled studies in pregnant women. First trimester: . Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.